Carcinoma, Ovarian Epithelial: all 1,619 studies

Page 7 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.

• Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian CancerStatus unknownNCT05375526Not applicable
• Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian CancerCompletedNCT05372692Not applicable
• Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian CancerStatus unknownNCT05371301Phase 3
• ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian CancerWithdrawnNCT05368506Early Phase 1
• Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingNCT05358639Phase 1
• The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian CancerTerminatedNCT05352217
• A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingNCT05335993Phase 2
• Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)TerminatedNCT05329545Phase 3
• A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionTerminatedNCT05325866Phase 1/2
• A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian CancerStatus unknownNCT05325229Phase 2
• A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor IndicationsTerminatedNCT05317078Phase 1
• CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)Active, not recruitingNCT05316181Phase 3
• Niraparib Plus Anlotinib for Recurrent Ovarian CancerStatus unknownNCT05311579Phase 2
• Chromosomal Instability in Ovarian CancerStatus unknownNCT05310357
• Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT05310344Phase 2
• Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian CancerCompletedNCT05300828
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedNCT05293496Phase 1
• Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy TreatmentStatus unknownNCT05274867
• A Study to Investigate LYL797 in Adults With Solid TumorsTerminatedNCT05274451Phase 1
• Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese PatientsStatus unknownNCT05273944Phase 1
• Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian CancerStatus unknownNCT05270720Phase 1
• The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort StudyStatus unknownNCT05265117
• An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted TherapyStatus unknownNCT05255861
• Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)Status unknownNCT05246020Phase 2
• Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian CancerTerminatedNCT05243524Phase 2
• Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian CancerTerminatedNCT05215496Phase 1
• Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual DiseaseActive, not recruitingNCT05212779
• Evaluation of Prognostic Factors for Tubo-ovarian Cancer in FranceCompletedNCT05204342
• APX005M in Patients With Recurrent Ovarian CancerWithdrawnNCT05201001Phase 2
• T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsActive, not recruitingNCT05200559Phase 1/2
• A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesActive, not recruitingNCT05199272Phase 1/2
• Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian CancerCompletedNCT05188781
• Mapping Sentinel Lymph Node in Initial Stages of Ovarian CancerStatus unknownNCT05184140Not applicable
• Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor DrugsStatus unknownNCT05175326
• A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian CancerStatus unknownNCT05170594Phase 2
• Artificial inTelligence in eNdometriosis-related ovArian Cancer and Precision Surgery in eNdometriosis-related ovArian CancerStatus unknownNCT05161949
• Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerStatus unknownNCT05158062Phase 2
• Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian CancerActive, not recruitingNCT05156892Phase 1
• miRNAs in High Grade Serous Ovarian CancerStatus unknownNCT05146505
• Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian CancerWithdrawnNCT05145569Phase 2
• A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian CancerStatus unknownNCT05145218Phase 3
• Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.CompletedNCT05130515Phase 2
• Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian CancerCompletedNCT05092763Not applicable
• Variance of HRD From Paired Ovarian CancerStatus unknownNCT05069818
• Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian CancerStatus unknownNCT05059782Not applicable
• Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedNCT05044871Phase 2
• Homologous Recombination Deficiency in Chinese Ovarian Cancer PatientsStatus unknownNCT05044091
• Exercise Preconditioning in Ovarian CancerTerminatedNCT05029154Not applicable
• Ask Questions (ASQ):Implementation of a Communication InterventionCompletedNCT05025748Not applicable
• Thiol-disulfide Homeostasis in Patients With Ovarian CancerCompletedNCT05011539
• Survival Impact of Internal Mammary or Supraclavicular LymphadenectomyCompletedNCT05005650
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)TerminatedNCT05001282Phase 1/2
• A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian CancerTerminatedNCT04999605Phase 1/2
• A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )Status unknownNCT04998760Phase 2
• Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian CancerStatus unknownNCT04986371
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
• Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOCStatus unknownNCT04983550Phase 2
• Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian CancerStatus unknownNCT04971421
• OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian CancerWithdrawnNCT04941378Phase 1
• Study of XB002 in Subjects With Solid Tumors (JEWEL-101)CompletedNCT04925284Phase 1
• Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP InhibitorsCompletedNCT04917744
• Targeted Physical Activity to Improve Mobility and Falls Risk in Women Living With Ovarian CancerStatus unknownNCT04911114Not applicable
• Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian CancerTerminatedNCT04907968Phase 1
• Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid TumorsCompletedNCT04902872Phase 1/2
• Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian CancerTerminatedNCT04891185Phase 2
• A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerWithdrawnNCT04889495
• Reprab Study: PLD + Trabectedin RechallengeStatus unknownNCT04887961Phase 2
• Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian CancerStatus unknownNCT04885270Phase 3
• Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian CancerStatus unknownNCT04864431Not applicable
• NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.TerminatedNCT04861181Phase 4
• A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal CancerStatus unknownNCT04846842Phase 2
• Study of DP303c Injection in Patients With Advanced Ovarian CancerStatus unknownNCT04828616Phase 2
• Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsTerminatedNCT04826198Phase 1/2
• Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex SequencingCompletedNCT04823871Not applicable
• 4FMFES-PET Imaging of Endometrial and Ovarian CancersCompletedNCT04823065Phase 1/2
• A Study to Evaluate the Combination of ATX-101 and Platinum-based ChemotherapyTerminatedNCT04814875Phase 1/2
• Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau TestStatus unknownNCT04812938
• Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerActive, not recruitingNCT04807166Phase 2
• Phase 1 Dose Escalation of ArtemiCoffeeCompletedNCT04805333Phase 1
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian CancersWithdrawnNCT04795596Phase 2/3
• Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to BevacizumabStatus unknownNCT04770376
• Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorStatus unknownNCT04734665Phase 2
• Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian CancerTerminatedNCT04729608Phase 3
• Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)TerminatedNCT04726332Phase 1
• Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04720807Phase 2
• A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian CancerCompletedNCT04718740Phase 1
• A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)TerminatedNCT04718675Phase 1/2
• A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian CancerTerminatedNCT04718376Phase 1
• Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian CancerCompletedNCT04716374
• Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5)Status unknownNCT04714931Not applicable
• OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OCActive, not recruitingNCT04713514Phase 2
• TH1902 in Patients With Advanced Solid TumorsActive, not recruitingNCT04706962Phase 1
• Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP InhibitorsActive, not recruitingNCT04675320
• Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian CancerStatus unknownNCT04670978Phase 2
• EP0057 in Combination With Olaparib in Advanced Ovarian CancerCompletedNCT04669002Phase 2
• Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk DetectionTerminatedNCT04668521

← Carcinoma, Ovarian Epithelial overview